Aquestive Therapeutics
AQST
190 hedge funds and large institutions have $357M invested in Aquestive Therapeutics in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 66 increasing their positions, 56 reducing their positions, and 19 closing their positions.
51% more capital inflows, than outflows
Capital inflows: $47.5M | Capital outflows: $31.4M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
18% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 56
3% more funds holding
Funds holding: 184 → 190 (+6)
2.74% more ownership
Funds ownership: 57.41% → 60.16% (+2.7%)
9% more call options, than puts
Call options by funds: $7.71M | Put options by funds: $7.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$7.78M |
| 2 |
HRT Financial
New York
|
+$6.47M |
| 3 |
D.E. Shaw & Co
New York
|
+$5M |
| 4 |
Millennium Management
New York
|
+$3.05M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Propel Bio Management
Los Angeles,
California
|
-$5.17M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$4.17M |
| 3 |
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.28M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.1M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.36M |
AQST Hedge Fund Activity: Q3 2026 in Review
190 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2026, worth a combined $357M — up 19% from $300M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AQST positions and 19 closed out — a net gain of 7 holders — while 66 added to existing stakes and 56 trimmed.
The largest buyer was Rosalind Advisors, adding an estimated $7.78M. The largest seller was Propel Bio Management, cutting an estimated $5.17M.
- 190 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2026, up from 184 in Q2 2026.
- Funds reported $357M of Aquestive Therapeutics stock for Q3 2026, up 19% quarter-over-quarter.
- 26 funds opened new Aquestive Therapeutics positions in Q3 2026 and 19 closed out, a net change of +7 holders.
- The largest Aquestive Therapeutics buyer in Q3 2026 was Rosalind Advisors, an estimated $7.78M added.
- The largest Aquestive Therapeutics seller in Q3 2026 was Propel Bio Management, an estimated $5.17M sold.
Based on aggregated 13F filings for Q3 2026.